阿替唑单抗
索拉非尼
医学
贝伐单抗
肝细胞癌
肿瘤科
临床试验
内科学
护理标准
同情性使用
癌
无容量
免疫疗法
伦瓦提尼
癌症
化疗
作者
Alessandro Rizzo,Angela Dalia Ricci,Giovanni Brandi
出处
期刊:Immunotherapy
[Future Medicine]
日期:2021-06-01
卷期号:13 (8): 637-644
被引量:65
标识
DOI:10.2217/imt-2021-0026
摘要
Advanced hepatocellular carcinoma (HCC) patients present poor prognosis. However, recent years have seen the advent of several novel treatments in this setting, where the role of immune checkpoint inhibitors has been investigated. Among these, the PD-L1 inhibitor atezolizumab in combination with bevacizumab has reported unprecedented results in treatment-naive patients with unresectable disease, with the recently published IMbrave150 Phase III trial showing the superiority of the combination over sorafenib monotherapy, and after having attended more than a decade of 'stagnation', the HCC medical community has a new standard of care. Herein, we examine the development and the impact of atezolizumab in advanced HCC, summarizing the mechanism of action, pharmacokinetics and recent evidence from Phase I to III clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI